MAP3K8 (Ab-400) Antibody

1. these data demonstrate that miR-130b represses vascular inflammation via targeting Tpl2 PMID: 28759810
2. Results show that the binding of miR-589-5p to the MAP3K8 3'-UTR inhibits MAP3K8 expression and suppresses CD90+ cancer stem cells characteristics in hepatocellular carcinoma. PMID: 27835990
3. RelAp43 interacts with the p105-ABIN2-TPL2 complex and we observe a strong perturbation of this complex in presence of M protein. PMID: 29084252
4. miRNA-509-3p mimics or inhibitor transfection tests in KGN cells further confirmed that miRNA-509-3p improved oestradiol (E2) secretion by inhibiting the expression of MAP3K8 PMID: 27002000
5. role of p105/Tpl2 signaling in lung homeostasis PMID: 26300007
6. rs1042058 GG Crohn's disease -risk polymorphism in TPL2 results in a gain-of-function by increasing TPL2 expression and signalling, thereby amplifying Pattern recognition receptor -initiated outcomes. PMID: 26215868
7. MAP3K8 is a direct target of miR-144-3p, and miR-144-3p downregulation is a factor in renal cell carcinoma progression through potentiation of MAP3K8 expression. PMID: 27717821
8. Taken together, these results suggest that Cot kinase might play a critical role in Helicobacter pylori type IV secretion apparatus-dependent early IL-8 secretion and CagA-dependent late IL-8 secretion as an alternative signaling molecule in the Erk pathway. PMID: 28361341
9. Studies indicate that Tpl2, a MAP3K, participates in a broad range of cancer-related signaling pathways and induces tumorigenesis and progression of many cancers. PMID: 25723737
10. the results of the present study demonstrated that the miR-509-3p RCC suppressor was a significant regulator of the MAP3K8 oncogene, suggesting that it may have a potential therapeutic role in the treatment of renal cell carcinoma PMID: 25815776
11. findings provide a novel perspective on the role of the IL-33/ST2/COT signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment PMID: 25531326
12. structurally versatile active site significantly impacts the design of potent, low molecular weight COT kinase inhibitors PMID: 25918157
13. TPL2 mediates the phosphorylation of a fraction of nucleophosmin at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state nucleophosmin levels. PMID: 24998852
14. MAP3K8 and miR-17-5p expression were inversely correlated with treatment response PMID: 24819603
15. COT interacts with and phosphorylates Pin1 on Ser16. Consequently, Pin1 Ser16 phosphorylation by COT increases cyclin D1 abundance and enhances tumorigenecity of MCF7 cells. PMID: 24265246
16. Aberrant expression of A-, B-, and C-RAF, and COT is frequent in PTC; increased expression of COT is correlated with recurrence of PTC. PMID: 25674762
17. Tpl2 overexpression and downregulation showed significant stimulatory and inhibitory effects on tumorigenic and metastatic potential of ADI PC cells. PMID: 25274482
18. Following epithelial injury, intestinal myofibroblasts sense innate or inflammatory signals and activate, via Tpl2, the cyclooxygenase-2 (Cox-2)-prostaglandin E2 (PGE2) pathway, which are essential for the epithelial homeostatic response. PMID: 25316791
19. High MAP3K8 expression affects obesity-induced adipose tissue inflammation without systemic effects. PMID: 24586913
20. Tpl2 regulates various inflammatory pathways by activating the ERK mediated MAP kinase pathway in innate immune cells such as macrophages and dendritic cells in humans but not in mice. PMID: 24642963
21. Coregulation of TLR2 and TLR6 expression correlating with local processing of versican, a proteoglycan TLR2/6 agonist linked to carcinoma progression. PMID: 24723682
22. data indicate that Tpl2 kinase is associated with and contributes to disease progression of clear cell renal cell carcinoma PMID: 23982215
23. this report have defined a novel network leading to ERK1/ERK2 activation in cysticfibrosis airway epithelial cells in response to P. aeruginosa that involves both the TPL2 and EGFR protein kinases and contributes to inflammation of CF airways. PMID: 24404585
24. MAP3K8 mediates the phosphorylation and repression of IRF3 homodimers to promote greater transcriptional activity through utilization of IRF3:IRF7 heterodimers. PMID: 24275658
25. High Tpl2 expression is associated with peritoneal dissemination in gastric tumor. PMID: 23828905
26. The protein kinase TPL2 is essential for ERK1/ERK2 activation and cytokine gene expression in airway epithelial cells exposed to pathogen-associated molecular patterns. PMID: 23527104
27. Authors report constitutive activation of MAP3K8 kinase-dependent pathways that regulate the magnitude and extent of inflammatory activity of monocytes/macrophages within myeloma niches. PMID: 23252623
28. TPL2 was found to antagonize oncogene-induced cell transformation and survival through a pathway involving p53 downstream of cJun N-terminal kinase (JNK) and be required for optimal p53 response to genotoxic stress. PMID: 23533274
29. Overexpression of MAP3K8 is associated with early-onset colorectal cancer. PMID: 23322277
30. High TPL2 expression is associated with tumor progression. PMID: 23125217
31. the role of Tpl2 in GPCR-mediated Ca(2+) signaling and cell migration PMID: 21868363
32. Cot protein is responsible for the constitutive Erk1/2 activation in the anaplastic large-cell lymphoma cells. PMID: 21741362
33. OPN knockdown chemosensitized MDA-MB-231 cells to CTX, which is dependent on p38 MAPK pathway activation PMID: 21539449
34. TPL2 kinase plays a critical role in the promotion of androgen depletion-independent prostate cancer progression. PMID: 21267413
35. Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells. PMID: 20945381
36. identification of MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines PMID: 21107320
37. Tensile strain and magnetic particle force application do not induce MAP3K8 and IL-1B differential gene expression in a similar manner to fluid shear stress in human mesenchymal stem cells. PMID: 20603871
38. MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cells PMID: 20227498
39. endogenous Tpl2 promotes efficient murine gammaherpesvirus 68 lytic replication through AP-1-dependent upregulation of RTA expression PMID: 19939924
40. Cot protein, expressed in HEK293 cells and immunoprecipitated, was used in a peptide-based substrate screening assay. The results of this assay suggested that Polo-like kinase 1 (Plk1) was a substrate of Cot. PMID: 19804365
41. contributes to LMP1-induced NF-kB signaling downstream of TRAF2 PMID: 11932422
42. suggest that the activation of different signaling pathways by Cot and other MAP3Ks may be regulated separately and may provide evidence for how such discrimination by one member of this kinase family occurs. PMID: 12138205
43. Tpl2 is inhibited by and is a partner of NFkappab p105 PMID: 12667451
44. hKSR-2, a new member of the KSR family, negatively regulates Cot-mediated MAP kinase and NF-kappaB pathway signaling PMID: 12975377
45. the COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity PMID: 14517305
46. optimal TPL-2 stability in vivo requires interaction with ABIN-2 as well as p105 PMID: 15169888
47. Data support a role for MAP3K8 activity in cellular transformation, but suggest that mutational activation of the gene is a rare event in lung cancer. PMID: 15287022
48. phosphorylation of Cot at Thr-290 is necessary but not sufficient for full kinase activity in the MEK/ERK pathway PMID: 15466476
49. Tpl2/Cot is overexpressed in large granular lymphocyte proliferative disorders but not other T-cell neoplasias. PMID: 15575964
50. These results indicate a distinction between TNF Receptor family members CD40 and TNFR1 in their utilization of MAP3Ks, and demonstrate TRAF-dependence of Tpl2 association with the CD40 receptor complex. PMID: 15670770

Show More

Hide All

HGNC: 6860

OMIM: 191195

KEGG: hsa:1326

STRING: 9606.ENSP00000263056

UniGene: Hs.432453